Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Significant Decrease in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOSGet Rating) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 48,000 shares, a decline of 82.9% from the February 13th total of 281,000 shares. Based on an average daily volume of 2,700,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.2% of the company’s shares are short sold.

Vivos Therapeutics Trading Down 3.2 %

NASDAQ VVOS opened at $0.35 on Friday. The stock has a market cap of $8.65 million, a PE ratio of -0.29 and a beta of 2.83. Vivos Therapeutics has a 12 month low of $0.31 and a 12 month high of $2.99. The stock’s 50 day moving average is $1.04 and its 200 day moving average is $0.84.

Vivos Therapeutics (NASDAQ:VVOSGet Rating) last posted its quarterly earnings data on Tuesday, December 20th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The firm had revenue of $4.25 million for the quarter. Vivos Therapeutics had a negative return on equity of 142.18% and a negative net margin of 155.58%. On average, analysts forecast that Vivos Therapeutics will post -1.06 EPS for the current fiscal year.

Institutional Trading of Vivos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new stake in shares of Vivos Therapeutics during the first quarter worth about $29,000. SeaCrest Wealth Management LLC purchased a new stake in Vivos Therapeutics in the 3rd quarter worth approximately $26,000. State Street Corp boosted its position in Vivos Therapeutics by 150.4% in the 1st quarter. State Street Corp now owns 45,650 shares of the company’s stock worth $122,000 after purchasing an additional 27,417 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Vivos Therapeutics by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 695,051 shares of the company’s stock worth $1,862,000 after buying an additional 31,798 shares during the period. 9.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on VVOS. Roth Capital reissued a “buy” rating on shares of Vivos Therapeutics in a research report on Wednesday, December 21st. Ascendiant Capital Markets assumed coverage on Vivos Therapeutics in a research report on Tuesday, January 17th. They set a “buy” rating on the stock.

Vivos Therapeutics Company Profile

(Get Rating)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Featured Articles

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with's FREE daily email newsletter.